Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities

被引:100
|
作者
Venhorst, J
ter Laak, AM
Commandeur, JNM
Funae, Y
Hiroi, T
Vermeulen, NPE
机构
[1] Vrije Univ Amsterdam, Dept Pharmacochem, Fac Sci, Div Mol Toxicol,Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands
[2] Osaka City Univ, Sch Med, Chem Lab, Abeno Ku, Osaka 545, Japan
关键词
D O I
10.1021/jm0209578
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The ligand-binding characteristics of rat and human CYP2D isoforms, i.e., rat CYP2D1-4 and human CYP2D6, were investigated by measuring IC50 values of 11 known CYP2D6 ligands using 7-methoxy-4-(aminomethyl)coumarin (MAMC) as substrate. Like CYP2D6, all rat CYP2D isozymes catalyzed the O-demethylation of MAMC with K-m and V-max values ranging between 78 and 145 muM and 0.048 and 1.122 min(-1), respectively. To rationalize observed differences in the experimentally determined IC50 values, homology models of the CYP2D isoforms were constructed. A homology model of CYP2D6 was generated on the basis of crystallized rabbit CYP2C5 and was validated on its ability to reproduce binding orientations corresponding to metabolic profiles of the substrates and to remain stable during unrestrained molecular dynamics simulations at 300 K Twenty-two active site residues, sharing up to 59% sequence identity, were identified in the CYP2D binding pockets and included CYP2D6 residues Phe120, Glu216, and Asp301. Electrostatic potential calculations displayed large differences in the negative charge of the CYP2D active sites, which was consistent with observed differences in absolute IC50 values. MD studies on the binding mode of sparteine, quinidine, and quinine in CYP2D2 and CYP2D6 furthermore concurred well with experimentally determined IC50 values and metabolic profiles. The current study thus provides new insights into differences in the active site topology of the investigated CYP2D isoforms.
引用
收藏
页码:74 / 86
页数:13
相关论文
共 50 条
  • [41] Investigation of cytochrome P450 2D mediated drug interactions in rat microsomes and intact hepatocytes
    Di Marco, A
    Laufer, R
    DRUG METABOLISM REVIEWS, 2003, 35 : 176 - 176
  • [42] Genetic structural and functional analysis of cytochrome P450s in the CYP2D gene family
    Wolf, CR
    Modi, S
    Lian, LY
    Paine, M
    Smith, G
    Roberts, GCK
    FASEB JOURNAL, 1997, 11 (09): : A773 - A773
  • [43] CYTOCHROMES P450 OF THE 2D SUBFAMILY IN RAT-BRAIN
    WYSS, A
    GUSTAFSSON, JA
    WARNER, M
    MOLECULAR PHARMACOLOGY, 1995, 47 (06) : 1148 - 1155
  • [44] The activity of cytochrome P450CYP2D in rat brain and the CYP2D2-mediated dopamine formation
    Daniel, W. A.
    Haduch, A.
    Bromek, E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S237 - S237
  • [45] Effects of cytochrome P450 (CYP) inducers and inhibitors on ondansetron pharmacokinetics in rats: involvement of hepatic CYP2D subfamily and 3A1/2 in ondansetron metabolism
    Yang, Si H.
    Lee, Myung G.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2008, 60 (07) : 853 - 861
  • [46] Cytochrome P450 fluorometric substrates: Identification of isoform-selective probes for rat CYP2D2 and human CYP3A4.
    Stresser, DM
    Turner, SD
    Blanchard, AP
    Miller, VP
    Crespi, CL
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (07) : 845 - 852
  • [47] A model for human cytochrome P-450 2D6 based on homology modeling and NMR studies of substrate binding
    Modi, S
    Paine, MJ
    Sutcliffe, MJ
    Lian, LY
    Primrose, WU
    Wolf, CR
    Roberts, GCK
    BIOCHEMISTRY, 1996, 35 (14) : 4540 - 4550
  • [48] Crystal structure of human cytochrome P450 2D6
    Rowland, P
    Blaney, FE
    Smyth, MG
    Jones, JJ
    Leydon, VR
    Oxbrow, AK
    Lewis, CJ
    Tennant, MG
    Modi, S
    Eggleston, DS
    Chenery, RJ
    Bridges, AM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (11) : 7614 - 7622
  • [49] The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine
    Davis, MP
    Homsi, J
    SUPPORTIVE CARE IN CANCER, 2001, 9 (06) : 442 - 451
  • [50] The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine
    Mellar P. Davis
    Jade Homsi
    Supportive Care in Cancer, 2001, 9 : 442 - 451